Literature DB >> 17713006

Gangliosides as immunomodulators.

Miroslava Potapenko1, Galina V Shurin, Joel de León.   

Abstract

Gangliosides are glycosphingolipids expressed at the outer leaflet of the plasmatic membrane of cells from vertebrate organisms. These molecules exert diverse biological functions including modulation of the immune system responses. Aberrant expression of gangliosides has been demonstrated on malignant cells. Besides expression on tumor cell membranes, gangliosides are also shed in the tumor microenvironment and eventually circulate in patients blood. Gangliosides derived from tumors posses the capability to affect the immune system responses by altering the function of lymphocytes and antigen-presenting cells and promoting tumor growth. These molecules can be considered as tumor weapons directed to attack and destroy immunosurveillance mechanisms devoted to control cancer progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17713006     DOI: 10.1007/978-0-387-72005-0_20

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  12 in total

1.  Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody.

Authors:  G M Piperno; A López-Requena; A Predonzani; D Dorvignit; M Labrada; L Zentilin; O R Burrone; M Cesco-Gaspere
Journal:  Gene Ther       Date:  2015-07-16       Impact factor: 5.250

2.  A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells.

Authors:  Ana Victoria Casadesús; Yuniel Fernández-Marrero; Marilyn Clavell; José Alberto Gómez; Tays Hernández; Ernesto Moreno; Alejandro López-Requena
Journal:  Glycoconj J       Date:  2013-04-02       Impact factor: 2.916

Review 3.  Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.

Authors:  Kayluz Frias Boligan; Circe Mesa; Luis Enrique Fernandez; Stephan von Gunten
Journal:  Cell Mol Life Sci       Date:  2014-12-07       Impact factor: 9.261

Review 4.  NGcGM3/VSSP vaccine as treatment for melanoma patients.

Authors:  Kirenia Pérez; Marta Osorio; Julio Hernández; Adriana Carr; Luis Enrique Fernández
Journal:  Hum Vaccin Immunother       Date:  2013-02-26       Impact factor: 3.452

5.  Glycolipid GD3 and GD3 synthase are key drivers for glioblastoma stem cells and tumorigenicity.

Authors:  Shih-Chi Yeh; Pao-Yuan Wang; Yi-Wei Lou; Kay-Hooi Khoo; Michael Hsiao; Tsui-Ling Hsu; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-03       Impact factor: 11.205

6.  MALDI imaging delineates hippocampal glycosphingolipid changes associated with neurotoxin induced proteopathy following neonatal BMAA exposure.

Authors:  Oskar Karlsson; Wojciech Michno; Yusuf Ransome; Jörg Hanrieder
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2016-12-09       Impact factor: 3.036

7.  Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis.

Authors:  Venkata Lokesh Battula; Yuexi Shi; Kurt W Evans; Rui-Yu Wang; Erika L Spaeth; Rodrigo O Jacamo; Rudy Guerra; Aysegul A Sahin; Frank C Marini; Gabriel Hortobagyi; Sendurai A Mani; Michael Andreeff
Journal:  J Clin Invest       Date:  2012-05-15       Impact factor: 14.808

Review 8.  Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.

Authors:  Nora Berois; Eduardo Osinaga
Journal:  Front Oncol       Date:  2014-05-23       Impact factor: 6.244

9.  Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer.

Authors:  Venkatrao Vantaku; Sri Ramya Donepudi; Chandrashekar R Ambati; Feng Jin; Vasanta Putluri; Khoa Nguyen; Kimal Rajapakshe; Cristian Coarfa; Venkata Lokesh Battula; Yair Lotan; Nagireddy Putluri
Journal:  Oncotarget       Date:  2017-09-16

10.  Silencing of GM3 synthase suppresses lung metastasis of murine breast cancer cells.

Authors:  Yuchao Gu; Junhua Zhang; Wenyi Mi; Jing Yang; Feng Han; Xinzhi Lu; Wengong Yu
Journal:  Breast Cancer Res       Date:  2008-01-03       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.